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AbsTRACT
Organoid cultures have emerged as an alternative in vitro 
system to recapitulate tissues in a dish. While mouse 
models and cell lines have furthered our understanding 
of liver biology and associated diseases, they suffer in 
replicating key aspects of human liver tissue, in particular 
its complex architecture and metabolic functions. Liver 
organoids have now been established for multiple 
species from induced pluripotent stem cells, embryonic 
stem cells, hepatoblasts and adult tissue-derived cells. 
These represent a promising addition to our toolbox to 
gain a deeper understanding of this complex organ. In 
this perspective we will review the advances in the liver 
organoid field, its limitations and potential for biomedical 
applications.
InTRoduCTIon
What are organoids? How can organoids benefit 
research?
The study of human organ development and diseased 
states is hampered by the inaccessibility of human 
samples in vivo and intrinsic differences between 
animal models and human biology. Advances in 
three-dimensional (3D) cell culture techniques 
facilitated by a deeper understanding of extracel-
lular matrix (ECM) biology combined with greater 
knowledge about signalling pathway regulation of 
stem cell niches and differentiation programmes 
have enabled the establishment of organoid culture 
systems. The term ‘organoid’ has previously been 
used to refer to a range of 3D culture systems 
which resemble the modelled organ to varying 
extents. Here we subscribe to the organoid defini-
tion coined by Lancaster and Knoblich1 and Huch 
and Koo2 to define an organoid as an in vitro 3D 
cellular cluster derived from tissue-resident stem/
progenitor cells, embryonic stem cells (ESCs) or 
induced pluripotent stem cells (iPSCs) capable of 
self-renewal and self-organisation that recapitulates 
the functionality of the tissue of origin. Organoids 
were named ‘Method of the year 2017’ by Nature 
Methods,3 reflecting the excitement and promise of 
this rapidly expanding field to provide new experi-
mentally tractable, physiologically relevant models 
of organ development, human pathologies and 
paving the way for therapeutic applications.
In the body, cells reside in complex microenvi-
ronments and are subject to numerous signalling 
interactions, including those from soluble factors, 
mechanical cues and the ECM. These interactions 
are key in establishing, maintaining and regulating 
cellular phenotypes and functions. It is now broadly 
accepted that cells cultured in 3D more closely 
resemble architectural and functional properties of 
in vivo tissues compared with cells cultured with 
two-dimensional (2D) techniques. One reason 
for this is the generation of cell–cell or cell–ECM 
interactions in all three dimensions, while in 2D 
monolayer cultures interactions are limited to the 
horizontal plane. Cells within a tissue are often 
exposed to concentration gradients of signalling 
effector molecules, nutrients and waste products; 
this is mimicked to an extent in 3D culture systems 
with the cells at the centre of an aggregate/organoid 
having less access to factors in the culture medium. 
Conversely, in 2D monolayers cells are exposed to 
a uniform concentration of factors due to direct 
contact with the culture medium. The establish-
ment of more physiological, biochemical and 
biomechanical microenvironments using 3D tech-
niques can affect cell proliferation, differentiation, 
morphogenesis, cell migration, mechanoresponses 
and cell survival.4 In terms of therapeutic applica-
tions, this may, in part, explain the failure of 2D 
cell culture systems to recapitulate drug screening 
outcomes as seen in vivo.5 Organoids represent a 
promising model system to bridge the gap between 
2D cultures and in vivo mouse/human models. 
Organoids are more physiologically relevant than 
2D culture models, while providing a reductionist 
model of in vivo biology in which it is possible 
to manipulate signalling pathways and perform 
genome editing.
Initiation of organoid culture requires the isola-
tion of stem/progenitor cells, either pluripotent 
stem cells (PSCs) or tissue-resident stem/progenitor/
differentiated cells isolated from embryonic stages 
or adult tissues (figure 1). The cells of origin for 
PSC-derived organoids are ESCs or iPSCs, which 
are then cultured in media supplemented with 
growth factors in order to mimic the signals that 
cells are exposed to during embryonic patterning to 
give rise to the specific tissue.
During development, a single totipotent cell, the 
zygote, which can form extraembryonic and embry-
onic tissues, proliferates and gives rise to progeny 
that overtime becomes increasingly lineage-re-
stricted. At the blastocyst stage the outer cells are 
committed to extraembryonic fates, while cells of 
the inner cell mass (ICM) are pluripotent and are 
competent to form all tissues of the embryo proper; 
it is these pluripotent ICM cells that are isolated to 
obtain ESCs.6 The next key developmental process 
is gastrulation, where cells derived from the ICM 
undergo extensive cell mixing and morphogenetic 
movements mediated by signalling factors such as 
Wnt, fibroblast growth factor (FGF) and trans-
forming growth factor-beta ligands to activate 
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transcriptional programmes and subsequent differentiation into 
the three germ layers: endoderm, mesoderm and ectoderm. 
Within the three germ layers progenitor cells become specified 
to form primordial organ structures, which give rise to all tissues 
and organs of the body. The identity of these progenitors is regu-
lated by signalling gradients of morphogens that are established 
along the anterior-posterior and dorsal-ventral axes of the devel-
oping embryo. The GI tract derives from the endodermal germ 
layer, and depending on the location of the endodermal progen-
itors they may generate tissues with anterior identities such as 
the lungs, or with more posterior identities such as the small 
intestine. This is due to anterior-posterior gradients of signal-
ling factors, including Wnt, retinoic acid, bone morphogenetic 
protein (BMP) and FGFs; dysregulation of these gradients can 
have drastic consequences, for example overactivation of the 
Wnt pathway causes more anterior endodermal progenitors to 
adopt hindgut fates, leading to the failure of liver formation.7 
Likewise, the fate of PSCs in culture can be influenced by the 
activation and inhibition of developmental signalling pathways 
to direct the stepwise in vitro differentiation of progenitors 
towards specific organ identities.
Organoids generated from tissue-resident stem/progenitor 
cells require culture conditions that resemble the stem cell 
niche during physiological tissue self-renewal or during damage 
repair, rather than recapitulation of developmental processes. In 
addition to use of carefully composed culture media, organoid 
systems require a specialised physical environment, which 
commonly involves culturing multipotent progenitor(s) in 
suspension, on an air–liquid interface or embedded in a suitable 
ECM such as Matrigel. Under these conditions, the multipotent 
progenitor(s) follows intrinsic developmental or homeostatic/
repair programmes to proliferate and self-organise into 3D 
organoid structures.
History of organoids
The rapid advances of the organoid field over the last 10 
years are built on decades of work to gain greater insight 
into PSCs, self-organisation of dissociated tissues and ECM 
biology.8 For example, Bissel and colleagues9 demonstrated 
that interactions with the ECM could improve hepatocel-
lular function of rat hepatocytes and regulate the growth 
and differentiation of mammary gland epithelia which, 
when embedded in ECM hydrogels, could develop tubules 
and ducts.10 11 Another demonstration of the importance 
of recapitulating cell–cell and cell–ECM interactions was 
the coculture of gastric epithelial cells and fibroblasts in an 
ECM hydrogel with an air–liquid interface. This method 
enabled the short-term culture of stomach tissue and facili-
tated the generation of differentiated gastric surface mucous 
cells.12 These early studies showed that 3D culture systems 
had the potential to support morphological rearrangements 
and differentiation of tissues but were limited to short-term 
cultures which could not self-renew.
Seminal work from the lab of Hans Clevers demonstrated 
that a single leucine-rich repeat-containing G-protein-coupled 
receptor 5 (Lgr5) positive adult stem cell isolated from mouse 
intestinal tissue could form a self-renewing culture that recapit-
ulated the intestinal crypt-villus architecture and cell composi-
tion, including mature functional cell types.13 The isolated stem 
cell was embedded in Matrigel as ECM and cultured in media 
supplemented with growth factors based on the endogenous 
intestinal stem cell niche. A key finding from this report was 
the inclusion in the culture media of R-spondin, an LGR4/5/6 
ligand that upregulates Wnt signalling, which helps to main-
tain stem cell populations. Since this initial finding, culture of 
human intestinal organoids has been achieved,14 and R-spondin 
containing media has been further optimised to support the 
Figure 1 Organogenesis and stages for organoid progenitor isolation. Schematic depicting key stages of organogenesis timings in mice and 
humans. Following fertilisation and cleavage of the embryo, the blastocyst is formed in which cells segregate into the outer layer and the inner 
cell mass (ICM). Cells of the ICM are pluripotent and can be isolated to generate embryonic stem cells. The next key developmental milestone is 
gastrulation, a process whereby cells derived from the ICM undergo dynamic cell movements and rearrange to form the three germ layers: endoderm, 
mesoderm and ectoderm. Here we depict a human gastrula which develops as an embryonic disc (note: gastrulation in mice occurs as an egg 
cylinder). As development progresses, progenitors within each germ layer become specified to give rise to specific tissues and organs. The identities 
of the progenitors are influenced by their anterior-posterior and dorsal-ventral positions in the embryo. The endoderm becomes patterned along the 
anterior-posterior axis into the anterior foregut (AF), posterior foregut (PF), midgut (M) and hindgut (H). Illustrated here are a selection of organs 
that derive from the different endodermal domains: AF—lungs; PF—liver and pancreas; M—small intestine. The hindgut gives rise to more posterior 
tissues such as the colon. Organoids can be derived from tissue-resident progenitors isolated at both organogenesis stages and from adult tissues. 
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generation of organoids from other organs with Lgr5+ progen-
itor cells, including the colon,14 stomach15 and liver,16among 
others.
Simultaneous to the development of organoids derived from 
tissue-resident progenitors/cells, ESCs were shown to generate 
cortical tissues when differentiated as 3D aggregates,17 which 
laid the foundation for the generation of cerebral organoids 
that could model aspects of human brain development in 
vitro.18 Since these reports, organoids from both PSCs as well 
as tissue-resident stem cells have been used to model many 
organs derived from the endoderm, mesoderm and ectoderm as 
reviewed in ref 19. Briefly we present a non-exhaustive list of 
organoid systems to date: organoids derived from the endoderm: 
thyroid,20 21 lung,22–24 stomach,15 25 26 liver,16 27–29 pancreas,30–33 
small intestine13 34 and colon14 35; mesoderm-derived organoids: 
kidney,36 bone,37 fallopian tube38 and endometrium39 40; and 
ectoderm-derived organoids: mammary gland,41 42 retinal,43–45 
brain,18 46 47 inner ear48 and salivary gland.49 In this perspective 
we will focus on the establishment of liver organoids, how they 
can be used to study liver development and disease, and their 
therapeutic potential.
Liver development, homeostasis and regeneration
The majority of the liver is composed of epithelial cells (hepato-
cytes and cholangiocytes) that work together with stromal, 
endothelial and mesenchymal cells to perform crucial meta-
bolic, exocrine and endocrine functions for body homeostasis. 
Our knowledge of liver development stems greatly from mouse 
studies, which despite intrinsic biological differences from human 
can guide researchers’ efforts to direct differentiation of liver 
progenitors and understand human development. During organ-
ogenesis liver embryonic progenitor cells (known as hepatoblasts) 
are specified from the posterior foregut endoderm. In response 
to signalling factors secreted by the surrounding mesenchyme, 
such as FGF, BMP, hepatocyte growth factor (HGF) and Wnt, 
hepatoblasts undergo cell shape changes, proliferate and migrate 
into the adjacent mesoderm to form the liver bud.50 During the 
course of liver bud outgrowth and the establishment of the lobes, 
hepatoblasts become lineage-committed in order to give rise to 
hepatocytes and cholangiocytes.51 Indeed, we recently reported 
that a single Lgr5+ hepatoblast can generate both hepatocytes 
and cholangiocytes, demonstrating the bipotency of hepatoblasts 
in vivo.52 The fate of hepatoblasts is influenced by local signal-
ling: subsets of hepatoblasts that are exposed to signals near the 
portal mesenchyme generate cholangiocytes, while hepatoblasts 
that are located further from the portal veins respond to signals 
from closely associated haematopoietic cells and give rise to 
hepatocytes.
To support normal functions, the adult liver must be maintained 
during homeostasis. In contrast to other endodermal organs such 
as the intestine that self-renew every 3–5 days, the liver has a 
much slower cellular turnover (in mice, approximately every 
60 and 150 days for cholangiocytes and hepatocytes, respec-
tively53). Homeostatic epithelial maintenance occurs primarily 
through the self-duplication of mature cells.54 55 Despite a low 
cellular turnover, when challenged, the liver has a remarkable 
ability to regenerate, although repeated damage to the tissue can 
result in impairment of liver function and fibrosis, as reviewed 
in ref 56. Upon partial hepatectomy (surgical resection of up to 
two-thirds of the liver), the remaining healthy mature hepato-
cytes respond to injury-induced regenerative signals such as 
tumour necrosis factor-alpha (TNFa) and interleukin-6 to prolif-
erate and undergo hyperplasia in order to restore tissue mass 
within a week.57 58 Understanding of this phenomenon has 
been taken into the clinic and helped to facilitate live donor 
transplants and tumour resections. However, on toxin-medi-
ated damage (eg, viruses and alcohol) or due to chronic liver 
pathologies such as non-alcoholic fatty liver disease (NAFLD), 
hepatocytes become impaired and are unable to undergo the 
mass proliferative response seen following partial hepatectomy. 
Incredibly, even when hepatocyte proliferation is compromised, 
the liver is still capable of regenerating itself. In this case, there 
is a ductular reaction in which ductal cells become activated and 
start to proliferate, repopulating the liver.59–62 Understandably, 
there has been a large effort to establish faithful in vitro liver 
models from PSCs and tissue-resident stem/progenitor/differen-
tiated cells to gain insights into liver biology and diseases and 
into regenerative mechanisms in general (figure 2).
Embryonic liver organoids as a tool to understand liver 
development
With the aim of replicating liver development in vitro, several 
groups have succeeded in differentiating human iPSCs into 
hepatocyte-like cells following a stepwise differentiation 
protocol based on several chemical inhibitors.63 An alternative 
approach was pursued by the Suzuki and Hui labs, which forced 
the expression of pioneer liver transcription factors (HNF4a 
and FOXA1,2,3)64 or (HNF4a, GATA4 and HNF1B)65 to induce 
the direct differentiation of iPSCs into hepatocyte-like cells in 
vitro. However, these early differentiation approaches were 
performed in 2D and lacked the 3D information required to 
form hepatic tissue in vitro. The first attempt to generate 3D 
liver tissue in culture that recapitulated embryonic liver features 
was the establishment of embryonic liver bud cultures by Takebe 
and colleagues,66 in which human iPSC-derived hepatocytes 
were cultured with mesenchymal stem cells and umbilical cord 
cells. The resulting liver bud organoids consisted of proliferating 
hepatoblasts and associated cells that, on transplantation into 
different mouse sites, developed into hepatic tissue exhibiting 
mature hepatic features.66 This system has since been refined 
so that the hepatic endoderm, mesenchymal and endothelial 
progenitors are all derived from iPSCs.67 Human iPSCs can 
also be directed via the exposure to specific signalling pathways 
to form cholangiocyte organoids.68 Due to the careful modu-
lation of culture media necessary to direct PSCs to a specific 
lineage, a major challenge that organoid models need to resolve 
is successful coculture of multiple cell types with different media 
requirements. Recently, hepatobiliary structures containing both 
hepatocyte and cholangiocyte cells have been derived from 
human iPSCs,69 70 although these structures do not self-renew. 
These reports may facilitate refinement of culture media to soon 
generate self-organising, self-renewing hepatobiliary organoids.
One limitation of iPSC-derived organoids for clinical use is 
the concern regarding genomic instability due to exposure to 
reprogramming factors.71 To negate this concern, organoids can 
be derived from embryonic or adult tissue-resident stem cells. 
We recently described the isolation of bipotent Lgr5+ embryonic 
hepatoblasts which retain the capacity to form either hepatocyte 
or cholangiocyte organoids depending on the culture medium 
used.52 Similarly, the establishment of hepatocyte organoids 
derived from bulk human embryonic liver tissue from aborted 
fetuses has been described.28 Further optimisation of culture 
conditions may enable the development of hepatobiliary organ-
oids from these tissue-resident stem progenitors. Hepatoblasts 
serve as the functional stem cell of the liver during development; 
however, they are not generally thought to persist postnatally. 
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Therefore, in order to recapitulate liver regeneration and 
diseased states in vitro, it may be beneficial to initiate cultures 
using cells isolated from primary adult liver tissue.
Liver organoids that recapitulate adult tissue and liver 
regeneration
Early studies by Michalopoulos and colleagues,72 in which 
isolated adult rat hepatocytes and other hepatic cells were placed 
in roller cultures, led to the formation of tissues resembling 
features of hepatic architecture; however, these cultures only 
survived for a short period of time. Self-renewing liver organoids 
demonstrating genetic stability during long-term culture were 
reported in 2013. Isolated healthy ducts (or Lgr5+ liver cells 
postdamage induction) self-organised into 3D structures which 
sustained long-term expansion as adult ductal progenitor cells 
while retaining the ability to differentiate into functional hepato-
cyte-like cells in vitro.16 The expansion of adult ductal liver 
organoids was enabled by use of an optimised culture medium. 
Figure 2 Liver organoids can be derived from various cells of origin by regulating signalling pathways during in vitro culture. (A) Liver organoids can 
be formed from tissue-resident cells isolated from biopsies of adult tissues or from embryonic stages during organogenesis. Hepatoblasts (the bipotent 
embryonic progenitors in vivo which give rise to ductal cells and hepatocytes) can be placed in Matrigel as ECM and generate ductal or hepatocyte 
organoids depending on the growth factors supplemented in the culture medium. (Bright-field images of mouse embryonic ductal and hepatocyte 
organoids taken from Prior et al.52) Signalling pathways which are typically modulated to enable organoid formation are listed; the pathways which 
are essential for different types of liver organoids are in bold. Formation of ductal or hepatocyte organoids from adult tissues requires the isolation of 
appropriate cells of origin. In order to generate ductal hepatic organoids from adult tissues, ductal fragments or ductal cells can be placed in Matrigel 
with the optimised media. Formation of adult hepatocyte organoids requires the isolation of mature hepatocytes. (B) Liver organoids can also be 
generated from pluripotent stem cells (iPSCs and ESCs), usually by a three-stage differentiation process that recapitulates the signalling programmes 
active during development. iPSCs/ESCs are first directed towards an endodermal fate by exposure to Act A and Wnt. These endoderm cells then 
progress to a hepatic fate following induction of HGF and FGF signalling. These hepatic progenitors are hepatoblast-like cells. The hepatic progenitors 
can form hepatocyte-like cells in response to OSM signalling. Conversely, by placing the hepatic progenitors in ECM and modulating FGF, EGF and Act 
A signalling, ductal organoids can be generated. Act A, Activin A; BMP, bone morphogenetic protein; ECM, extracellular matrix; EGF, epidermal growth 
factor; ESCs, embryonic stem cells; FGF, fibroblast growth factor; FSK, forskolin; HGF, hepatocyte growth factor; ICM, inner cell mass; iPSCs, induced 
pluripotent stem cells; OSM, Oncostatin M; TGFbi, transforming growth factor beta inhibitor; TNFa, tumour necrosis factor-alpha.   
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In addition to the epidermal growth factor and Wnt agonists, 
which had been shown to be important for organoid derivation 
from Lgr5+ intestinal stem cells,13 signalling factors important 
for liver development, HGF and FGF, were supplemented in 
the culture medium. This protocol was subsequently adapted to 
generate liver organoids from healthy human primary tissue27 
and to generate disease models from primary liver cancer (PLC) 
(discussed below).73 Recently, the Nusse and Clevers labs have 
described the long-term culture of primary mouse hepato-
cytes,28 29 which retain many morphological and functional 
properties of hepatocytes. The system proposed by Hu et al28 
uses increased R-spondin and FGF signalling to produce hepato-
cyte organoids that have expression profiles similar to those of 
hepatocytes after partial hepatectomy. The model demonstrated 
by Peng et al29 was based on observations that during liver injury, 
liver-resident macrophages secrete high levels of inflammatory 
cytokines, including TNFa, to aid regeneration. Culture with 
TNFa indeed served to enhance expansion of hepatocytes.29
In addition to liver organoid generation from mouse and 
human cells, adult ductal organoids have also been generated 
from rats,74 cats75 and dogs76; for an extended review on liver 
organoids from other species please see ref 77. Since several liver 
pathologies progress in a similar manner in cats and dogs as in 
humans, use of organoids from these species may provide insight 
to advance human therapies while not being subject to the same 
level of ethical constraints.
These advances in liver organoid technology are providing 
models for prenatal development, tissue maintenance and 
pathologies, which are otherwise intractable processes to study 
in human. Below we discuss the biomedical applications of liver 
organoids, including their use for disease modelling (of both 
monogenic and acquired liver diseases), drug screening, toxi-
cology studies and regenerative medicine (figure 3).
disease modelling
Monogenic liver diseases
Monogenic liver diseases are caused by mutations in single 
genes. While these are considered ‘rare’ conditions, they account 
for 10 in every 1000 births.78 These represent a heterogeneous 
group of diseases that, according to the extent of the damage to 
the parenchyma and/or specific liver expression, can be classified 
into three groups: (1) conditions associated with predominant 
liver parenchymal damage, (2) disorders in which liver architec-
ture is near normal, and (3) genetic defects with both hepatic and 
extrahepatic manifestations.78
Within the monogenic diseases with both intrahepatic and 
extrahepatic manifestations, cystic fibrosis (CF) was the first 
human monogenic disease modelled with organoids, specifically 
using human intestinal organoids derived from rectal biopsies 
of patients with CF.79 The disease is caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) 
gene, which codes for a chloride channel normally expressed 
in epithelial cells of many organs, including on the surface of 
cholangiocytes and bile duct cells. Mutations in the CFTR gene 
impair cholangiocyte chloride transport, leading to a lack of alka-
linisation and subsequent blockage of biliary ducts in the liver.80 
Dekkers and colleagues79 showed that CF intestinal organoids 
recapitulated the disease in vitro when cultured with an inducer 
of intracellular cyclic AMP (cAMP), called forskolin, thereby 
activating CFTR function. While healthy organoids responded 
to cAMP by importing fluid to the organoid lumen causing it 
to swell, this response was abolished in CF intestinal organoids. 
Subsequently, Sampaziotis and colleagues68 and Ogawa and 
colleagues81 also showed that cholangiocyte organoids gener-
ated from iPSCs of patients with CF carrying the most common 
mutation in CFTR (ΔF508) could also be used to model CF in 
vitro. Similar to the small intestinal organoids, CF cholangiocyte 
organoids also lacked the ability to swell in response to forskolin.
Within the panoply of monogenic liver disorders, alpha-1-
anti-trypsin (A1AT) deficiency, Wilson’s disease and Alagille 
syndrome are three examples of diseases that affect the liver 
parenchyma (for an extensive review on monogenic liver 
diseases, please see ref 78). Organoids derived from adult liver 
tissue from patients with either A1AT deficiency or Alagille 
syndrome or dogs with a special form of Wilson’s disease have 
been successfully developed and recapitulate key aspects of the 
diseases modelled.27 76 Specifically, differentiated liver organoids 
from patients with A1AT deficiency accumulate protein aggre-
gates, similar to what had been observed in the original biopsy.27 
Liver organoids derived from biopsies from patients with Alagille 
syndrome,27 or generated by differentiation from iPSCs from 
patients with Alagille syndrome,82 mirrored the in vivo biliary 
defects that characterise the disease. In addition, liver organoids 
established from a mouse model of Alagille syndrome (JAG1 
mutants) showed that the mutation caused a delay in the ability 
of organoids to differentiate into mature cholangiocytes and a 
failure to form and maintain biliary ducts.83 These studies are 
proof-of-principle that liver organoids recapitulated key features 
of the disease in vitro and enable further understanding of the 
disease processes.
Acquired liver diseases
Liver organoids were first exploited as tools to model monogenic 
liver diseases, but recently the 3D structures have been success-
fully used to model complex acquired liver diseases, including 
PLC and viral hepatitis.
Cancer
PLC, the second most lethal malignancy worldwide, includes 
a heterogeneous group of tumours with distinct histological 
features and poor prognosis rates: hepatocellular carcinoma 
(HCC) represents 80% of all PLCs, followed by cholangiocar-
cinoma (CC). A combined hepatocellular-cholangiocarcinoma 
subtype (HCC/CC) accounts for 0.4%–14.2% of all PLCs. 
PLCs are characterised by a complex and diverse landscape 
of genetic—including high degree of aneuploidy, DNA copy 
number variations, somatic mutations—and epigenetic alter-
ations that drive neoplastic transformation and growth,84 further 
supporting the need for patient-tailored therapeutics, also called 
personalised medicine. The multikinase inhibitor sorafenib85 
and more recently lenvatinib86 are the only two approved first-
line therapies for HCC in the USA. Currently, no target thera-
pies are approved for CC. Frequent genetic alterations in PLCs, 
both HCC and CC, include those in the TP53 and cell cycle-re-
lated genes, such as CCND1 and CDKN2A, and in the chro-
matin-remodelling genes ARID1A and ARID2. HCC is further 
characterised by activating mutations in components of the 
WNT/CTNNB1 pathway, while CC is frequently altered in the 
EGFR and KRAS genes.84
For decades, research into PLCs depended on 2D cell culture 
systems and transgenic mouse models. While these have 
proven useful to advance our understanding of the disease, 
both approaches are markedly limited. PLC is genetically 
heterogeneous, as shown by sequencing studies, a feature that 
the limited number of existing cells lines fail to reproduce. In 
fact, the establishment of cell lines represents a bottleneck of 
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the heterogeneous genomic landscape of PLCs, as only the 
clones with the most beneficial mutations are amenable to in 
vitro culture. Moreover, 2D cell lines are unable to mimic the 
histoarchitecture of the tumours. Genetically engineered mouse 
models (GEMM) have provided insights into the biology of the 
disease; however, they are time-consuming, costly and cannot 
recapitulate all the human tumour traits. Patient derived xeno-
grafts (PDXs), in which cells from a patient are transplanted 
into immunocompromised mice, have been established for both 
(HCC and CC) as alternative approaches to GEMM.87 PDXs 
recapitulate the genetic and histological features of the original 
tumour,88 and if engrafted into humanised mice may help infer 
the interactions between tumour and immune cells.89 The PDX 
approach has been used with great success to study resistance 
mechanisms and test different therapeutics.90 91 However, while 
PDXs show great translational potential to direct treatment in 
a patient-tailored manner, this strategy has several drawbacks: 
PDXs are not amenable to large-scale drug screens, are costly 
and can take a considerable amount of time to establish.
By adapting the initial protocol to expand adult liver ductal 
progenitor cells,27 we successfully established primary liver 
tumour organoids in vitro—called tumouroids—from tumour 
resections (∼1 cm3 tissue) of eight patients with PLC, including 
its main three subtypes: HCC, CC and HCC/CC.73 The cultures 
Figure 3 Applications of liver organoids. (A) Organoids derived from healthy donors or patients can be used as a model in basic research to 
investigate liver development and function in healthy conditions and to dissect the mechanisms of disease. Liver organoids are also a potential 
bridging tool towards personalised medicine, allowing for patient-specific drug screening and gene therapy. (B) Organoids can be expanded in vitro 
and cryopreserved enabling the establishment of biobanks. These can be used on a larger scale for regenerative medicine (including transplants), 
drug screening (patient-derived organoids can help identify drugs that a cohort of patients are most likely to respond to) and toxicology studies for 
predicting which potential therapies may induce drug-induced liver injury. 
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expanded long term (~1 year), and preserved the histological 
architecture, gene expression patterns and genetic alterations 
seen in the patient tumour tissue of origin. Importantly, the 
tumouroids maintained tissue-of-origin features over time; 
global exome sequencing showed that over 90% of the genetic 
alterations in the patient’s tumour tissue were maintained in the 
respective tumouroids when in culture for less than 2 months 
and over 80% after 4 months. Furthermore, tumouroids reca-
pitulated the metastatic potential of the original tumour when 
transplanted into immunocompromised mice. In addition, 
comparative gene expression profiling of tumouroids versus 
healthy liver organoids enabled the identification of novel genes 
with prognostic value in liver cancer cohorts. These studies 
demonstrated that liver tumour organoids could be used to iden-
tify novel genes with a potentially important role in human liver 
cancer.
In addition, tumouroids were tested for their potential as a 
platform for drug screening and validation of candidate thera-
pies73; tumouroids responded with varying levels of sensitivity, 
supporting their use as platform for drug sensitivity testing 
in a patient-specific manner, opening the doors for precision 
oncology. The impact of the different sensitive compounds in 
healthy tissue remains to be tested. This can be achieved using 
healthy organoids as a platform to dissect the potential side 
effects of candidate therapies, a promising yet unexplored goal. 
While the PLC-derived organoids support the broad-ranging 
translation potential of organoids into the clinics, the limited 
number of samples used calls for further validation in more 
patients. Whether tumouroids may also help identify thera-
pies for metastases remains to be investigated. Unfortunately, 
we were unable to establish tumouroids from very well-dif-
ferentiated tumours (with less than 5% of proliferating cells), 
precluding drug testing for less advanced tumours. Whether 
refining the medium conditions may facilitate the establishment 
of tumouroids from very well-differentiated tumours remains 
to be determined.
In a parallel study, Nuciforo and colleagues92 elegantly 
showed that long-term organoid cultures can be established from 
fine needle biopsies from patients with HCC. These organoids 
retained the morphology, expression pattern and genetic hetero-
geneity of the originating tumours. Similarly, PLC tumouroids 
have also recently been established from 91 mouse liver tumour 
tissues, in what represents the largest collection of liver tumour 
organoids ever reported. In this study, Cao and colleagues93 
successfully used the generated organoids to assess anticancer 
drug responses, showing again that liver cancer organoids 
recapitulate the heterogeneous therapeutic responses that are 
observed in patients.
Of note, PLC, in particular CC, is characterised by a high 
degree of stromal reaction and desmoplasia. Unfortunately, all 
PLC tumour organoid cultures developed until now have only 
focused on expanding the epithelial counterpart of the tumour, 
and whether other tumour cell types can be incorporated in 
the structures and recapitulate the histopathological character-
istics of the tumours in the dish is still to be investigated. In 
that regard, pancreas cancer organoids established by Boj et al32 
have recently been cocultured with stromal cells,94 yet in this 
report the cells showed little cell–cell contact and were mainly 
segregated in the well, with the stromal cells adhering to the 
bottom of the plate. Whether coculturing epithelial and non-ep-
ithelial tumour tissue together could give rise to a structural 
architecture that would recapitulate the tumour of origin and 
the severe desmoplasia present in these tumours still remains to 
be determined.
Liver infections
The liver is the target organ of many viruses and of the Plas-
modium parasite, the agent causing malaria. Research has relied 
heavily on human hepatoma cell lines and humanised mouse 
models, but these are poor systems to recapitulate the complex 
biology of hepatocytes, difficult to obtain and highly costly, and 
not practical for large drug screening purposes.95 Liver organoid 
cultures recapitulate to some extent the complexity and archi-
tecture of the liver and may offer novel insights into the interac-
tions between the host and Plasmodium. In that regard, recent 
studies using iPSC-derived liver organoids have shown how 
these are a suitable in vitro culture system to study and model 
HBV96 and HCV97 infections. Differentiated liver organoids 
retain the innate immune responses and maintain cell polarity of 
hepatocytes, recapitulating the natural entry of HBV and HCV 
and allowing their cell-to-cell transmission. While the 3D liver 
organoids recapitulate host–virus interactions more faithfully 
than the standard in vitro models to date, whether they can be 
used for screening antiviral treatments or propagating the virus 
in culture awaits further investigation.
Regenerative medicine
Currently orthotopic liver transplantation is the only effective 
treatment for end-stage hepatic failure.98 However, a shortage of 
healthy tissue suitable for transplantation makes it impractical to 
implement as a routine therapy. Moreover, the patient receiving 
the transplant often needs to undergo long-term immunosup-
pression therapies.99 The expansion and differentiation potential 
of liver organoids makes these an alternative source of function-
ally mature and easily expandable cells for transplantation, over-
coming the current limitations. Huch and colleagues16 provided 
the first evidence for the potential of bile duct-derived organoids 
as a cell therapy, first with mice and later with human-derived 
organoids.27 After in vitro expansion and differentiation towards 
the hepatocyte fate, mouse cells were successfully transplanted 
into a fumarylacetoacetate hydrolase (FAH)−/− mutant mice, a 
mouse model of hereditary tyrosinemia type I.16 Lack of FAH 
leads to liver failure, unless the mice are administered NTBC 
(2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione). 
Although FAH-positive clusters occupied a modest 1% of the 
liver mass, the transplant significantly increased the survival of 
engrafted mice compared with control mice, serving as a proof-
of-principle for the use of in vitro liver organoids for cell therapy. 
Similar results were obtained following transplantation of human 
bile duct-derived organoids into mice.27 While groundbreaking, 
the differentiation efficiency from ductal cells into hepatocytes 
was limited. Recently, and as described above, two studies have 
established a second generation of hepatic organoids (hep-orgs) 
using primary hepatocytes. Both hep-orgs presented high 
engraftment capacity.28 29 Mouse hep-orgs exhibited an 80% 
engraftment of the mouse liver parenchyma when harvested at 
103 days post-transplantation,29 a marked improvement over 
the previous engraftment rate seen with ductal organoids.27 
Similarly, human embryonic hep-orgs also presented a superior 
engraftment ability with 10 µg/ml of albumin secreted to the 
mouse bloodstream at day 45 after transplantation28 compared 
with 100 ng/ml of protein reported from ductal organoids.27
Future studies are needed to identify the signals driving the 
proliferation of transplanted hepatocyte organoids. Whether 
hep-orgs maintain their proliferating and engraftment capacity 
when transplanted into more clinical settings, namely chronically 
damaged livers marked by inflammation and fibrosis, will require 
further investigation. In these cases, how a proinflammatory 
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and/or fibrotic environment may affect the ability of the trans-
planted cell to proliferate and engraft might represent a big chal-
lenge ahead. A modification of Huch et al’s original protocol27 
allowed Sampaziotis and colleagues100 to isolate and propagate 
human cholangiocytes from the extrahepatic biliary tree. Theses 
biliary organoids were able to reconstruct the gallbladder wall 
and repair the biliary epithelium following transplantation into 
the mouse. These studies represent a major step forward in our 
ability to expand functional hepatocytes and cholangiocytes for 
therapeutic applications.
drug discovery and personalised medicine
The disease modelling capacity of liver organoids, either gener-
ated from adult stem cells or iPSCs (box 1), has opened the door 
for liver organoids as a platform for drug screening and toxi-
cology tests.
As previously discussed, using PLC tumouroids researchers 
were able to identify, on a small scale, the tumour’s sensitivity 
to different therapies,73 a proof-of-principle that liver organoids 
might be applicable to patient-tailored treatments. Along these 
lines, an emerging application for liver organoids is the creation 
of biobanks that can be used as screening platforms to identify 
drug efficacy against PLCs and potentially other liver diseases. 
Liver organoid biobanks can also be established from healthy 
liver cells and used as a platform for predicting drug-induced 
liver injury (DILI), the main reason for acute liver failure and 
the primary cause of drug removal from the market.101 While 
human primary hepatocytes are currently the ‘gold-standard’ 
for drug metabolism and toxicity testing, their availability and 
long-term culture are limited. The newly established human 
embryonic hep-org represents a potential step forward for the 
pharmaceutical industry in their quest to assess new therapies for 
potential DILI. In that regard, whether embryonic human liver 
organoids develop to adult stages or whether mouse adult organ-
oids recapitulate their human counterparts and express all the 
metabolising enzymes required to assess human DILI remains to 
be investigated.
ConCLusIons And FuTuRE dIRECTIons
While liver organoids recapitulate key aspects of the liver 
(eg. architecture, certain functions and genetic signature) their 
use in biomedical applications on a large scale is still limited by 
our current inability to control organoid size, shape and cell 
composition (box 1). Use of liver organoids as a potential strategy 
for regenerative medicine is dependent on their reproducibility, 
scalability and safety as much as their cost-effectiveness. Bioen-
gineering holds great promise to generate liver organoids that 
are more physiologically relevant but also more amenable to 
biomedical applications.19
Harnessing the potential of liver cells to generate liver organ-
oids has fuelled our ability to recapitulate in vitro the epithe-
lial cells of the liver. However, disease modelling of complex 
diseases, such as PLCs where the microenvironment is key, 
calls for the generation of multicellular liver organoids where 
the epithelial cells interact with endothelial, mesenchymal and 
immune cells. Working closely with bioengineers to incorporate 
blood vessels into liver organoids could be seen as a must, and 
clearly a potential strategy to address the limited nutrient avail-
ability that ultimately comes into play when growing organoids.
The potential of liver organoids as tools to model other key 
chronic liver diseases, namely NAFLD and liver fibrosis, is a 
promising but yet unexplored field. NAFLD has taken the lead 
as the most common chronic liver disease in developed coun-
tries,102 encompassing a broad and progressive spectrum of liver 
histological alterations—from fatty liver (steatosis) to non-alco-
holic steatohepatitis (NASH)—which is an established risk factor 
for both HCC103 104 and CC.105 An additional strong predictor of 
liver-related mortality risk in NAFLD106 is fibrosis (an abnormal 
although reversible deposition of ECM proteins). Despite its 
high prevalence, little is known about the mechanisms under-
lying NAFLD and its progression into NASH in the human liver. 
A recent report from Takebe’s lab has shown that iPSCs differ-
entiated into hepatocyte organoids recapitulate some aspects 
of NAFLD and NASH in vitro, namely lipid accumulation and 
fibrosis, on treatment with free fatty acids.107 This system holds 
the potential to be used as a platform for drug testing and iden-
tification of potential new therapeutics for this highly preva-
lent disease. However, whether these iPSC-derived hepatocyte 
organoids can recapitulate the progressive nature of NAFLD to 
NASH, and subsequent step from NASH to cirrhosis and HCC, 
which in patients requires years, still awaits further investigation. 
Transplantation of these organoids into mice might facilitate that 
progression. Whether patient-derived liver organoids, if proven 
able to recapitulate the features of the disease, may help find 
biomarkers for risk progression into NASH and infer patient-tai-
lored therapeutics remains to be studied.
Several liver diseases, including liver cancer, experience 
significant epigenetic changes that modify the epigenetic land-
scape of the liver cells.108 Whether adult tissue-derived liver 
organoids and/or iPSC-derived 3D liver organoids maintain 
the epigenetic signature of these diseases and whether they 
can be used to investigate the role played by epigenetic modi-
fiers in disease initiation and progression remains to be deter-
mined. In that regard, engineered BAP1 mutations in healthy 
liver organoids have recently enabled the identification of the 
role of the epigenetic modifier BAP1 in CC.109 In this study, 
box 1 Liver organoids as liver disease modelling tools: 
advantages and current limitations
Advantages.
 ► Three-dimensional spatial organisation (ASCs/iPSCs).
 ► Genetically stable (ASCs).
 ► Preservation of genetic and epigenetic signature of derived 
tissue (ASCs).
 ► Long-term culture (ASCs/iPSCs).
 ► Biobanks (ASCs/iPSCs).
 ► Safe for transplantation (ASCs).
 ► Unlimited source of patient-derived cells (iPSCs).
 ► Non-invasive derivation from a variety of cells (eg, skin/
fibroblasts/blood cells) (iPSCs).
 ► Recapitulate different aspects of liver development (iPSCs).
 ► Disease modelling (ASCs/iPSCs).
 ► High-throughput drug screening (ASCs/iPSCs).
 ► Personalised medicine (ASCs/iPSCs).
 ► Gene therapy (ASCs/iPSCs).
Current limitations.
 ► Persistence of fetal markers (iPSCs).
 ► Limited cell maturation (ASCs/iPSCs).
 ► Restricted access to tissue and need for invasive methods 
(ASCs).
 ► Failure to recapitulate the multiple cell types of the liver 
(ASCs).
ASCs, adult stem cells; iPSCs, induced pluripotent stem cells. 
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BAP1, a predicted histone deubiquitinase, was found to control 
epithelial integrity through the regulation of chromatin acces-
sibility, which results in an acquisition of malignant features in 
organoids already harbouring other CC mutations.109 Similarly, 
postnatal tissue-derived intestinal organoids have been shown 
to retain the epigenetic landscape (methylome) of the tissue of 
origin.110
In conclusion, liver organoids, whether derived from PSCs, 
embryonic or adult healthy or diseased tissue, are providing 
excellent opportunities to study human liver in an unprecedented 
manner. Parallel to furthering our fundamental understanding of 
liver development, biology and disease, human liver organoids 
excel as promising tools for a wide range of biomedical applica-
tions, from disease modelling of rare disorders to personalised 
medicine or cell therapy. This exciting challenge will require a 
multidisciplinary approach, with biologists, clinicians and bioen-
gineers working closely to further understand how liver cells can 
self-organise to build the liver, one of the most complex organs 
in our body.
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